Novozymes is strengthening its BioHealth business with the acquisition of a majority stake in Synergia Life Sciences, a leading developer and manufacturer of vitamin K2 and probiotics.
Synergia Life Sciences Pte. Ltd. is a leading player in the field of vitamin K2-7 and spore-forming probiotics. Synergia has three production sites in India and services customers globally.
By acquiring Synergia Life Sciences, Novozymes accelerates its position in human health and functional foods, and bolsters its developing and manufacturing capabilities. The vitamin K2-7 portfolio is a strong complementary enabler to support growth in Novozymes’ BioHealth platform. Novozymes will continue to offer natural vitamin K2 to B2B customers under the MenaquinGold® ingredient brand.
Read the full press release here.